In this regard, anti-ORM2 blockades (e.g., small molecules or monoclonal Abs) could be novel candidates for the treatment of RA and other inflammatory diseases in which ORM2 plays a key role. The gene discussed is ORM2; the disease is rheumatoid arthritis.